Investigational drug · Phase 3
QY201
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Adult Subjects With Non-Segmental Vitiligo, Atopic Dermatitis (AD), Adolescent Participants With Moderate to Severe Atopic Dermatitis (AD).
Phase 3Last checked: Nov 19, 2026Latest source record: Jul 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
2 still active
All registered trials
4
Any phase or sponsor naming "QY201"
First trial start
2025
Mar 12, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "QY201", any sponsor or status.
Conditions studied
As listed on its trial records.
- Adult Subjects With Non-Segmental Vitiligo
- Atopic Dermatitis (AD)
- Adolescent Participants With Moderate to Severe Atopic Dermatitis (AD)
Approved drugs for the same conditions: Atopic dermatitis (eczema) · Immunology and inflammation · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "QY201" as an intervention, largest first.
- A Phase III Clinical Study of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis.Pivotal-lookingEnrolling by invitation
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.Industry
NCT07180511 · 460 participants (planned) · Start Mar 12, 2025 · Primary completion May 18, 2027
Drug: 10mg QY201 Placebo tablet; 20mg QY201 Placebo tablet and 2 more · For: Atopic Dermatitis (AD)
Sites: Hangzhou, China
- A Study of QY201 Tablet in Subjects With Moderate to Severe Atopic DermatitisPivotal-lookingStatus unknown
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.Industry
NCT05525715 · 260 participants (planned) · Start Oct 2022 · Primary completion Dec 2025
Drug: 2mg QY201 tablets or 2mg QY201 placebo,BID; 5mg QY201 tablets or 5mg QY201 placebo,BID and 8 more · For: Atopic Dermatitis
- A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of QY201 Tablets in Subjects With Non-Segmental VitiligoPivotal-lookingRecruiting
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.Industry
NCT07712523 · 200 participants (planned) · Start Nov 5, 2025 · Primary completion Dec 31, 2026
Drug: QY201 Tablets(5mg); QY201 Tablets(10mg) and 2 more · For: Adult Subjects With Non-Segmental Vitiligo
Sites: Shenyang, China
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.Industry
NCT07712536 · 24 participants · Start Jun 4, 2025 · Primary completion Dec 19, 2025
Drug: QY201 Tablets(10mg); QY201 Tablets(20mg) · For: Adolescent Participants With Moderate to Severe Atopic Dermatitis (AD)
Sites: Hangzhou, China
Newest research
PubMed records naming it or its code names, newest first.
- Efficacy and safety of QY201, an oral dual Janus kinase 1/tyrosine kinase 2 inhibitor, in adults with moderate-to-severe atopic dermatitis: a multicenter, randomized, double-blind, placebo-controlled phase 2 dose-finding trial.
Wang T, Li J, Liang Y, et al. · J Am Acad Dermatol 2026
- The Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of Orally Dosed QY201, a Novel JAK1/TYK2 Inhibitor, in Chinese Healthy Subjects.
Wang JY, Gao YH, Ruan ZR, et al. · J Clin Pharmacol 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.